title: Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
authors.affiliation: Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Cavo
authors.affiliation: Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Pantani
authors.affiliation: Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Pezzi
authors.affiliation: Azienda Policlinico Umberto I, University La Sapienza, Roma, Italy.
authors.forename: M T
authors.initials: MT
authors.lastname: Petrucci
authors.affiliation: Hematology and Bone Marrow Transplant Unit, Udine, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Patriarca
authors.affiliation: Department of Clinical and Molecular Bio-Medicine, University of Catania, Catania, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Di Raimondo
authors.affiliation: Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Marzocchi
authors.affiliation: Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Galli
authors.affiliation: Hematology-Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Montefusco
authors.affiliation: Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Zamagni
authors.affiliation: Arcispedale S. Maria Nuova, Hematology, Reggio Emilia, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Gamberi
authors.affiliation: Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Tacchetti
authors.affiliation: Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Brioli
authors.affiliation: University of Torino, Azienda Ospedaliero-Universitaria (AOU) S. Giovanni Battista Torino, Torino, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Palumbo
authors.affiliation: Department of Hematology, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Sonneveld
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D060828:Induction Chemotherapy; D009101:Multiple Myeloma / Q000628:therapy*; D013792:Thalidomide / Q000008:administration & dosage; D014182:Transplantation, Autologous
chemical_list: D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide